These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 29617004)

  • 1. Impact of Chronic Kidney Disease on Cardiovascular and Renal Events in Patients Undergoing Percutaneous Coronary Intervention with Everolimus-Eluting Stent: Risk Stratification with C-Reactive Protein.
    Dan K; Miyoshi T; Nakahama M; Mizuno T; Kagawa K; Naito Y; Kawada S; Ito H
    Cardiorenal Med; 2018; 8(2):151-159. PubMed ID: 29617004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-year clinical outcomes of the NOBORI biolimus-eluting stents versus XIENCE/PROMUS everolimus-eluting stents in small vessel disease.
    Jinnouchi H; Kuramitsu S; Shinozaki T; Hiromasa T; Kobayashi Y; Morinaga T; Yamaji K; Soga Y; Shirai S; Ando K
    Catheter Cardiovasc Interv; 2016 Nov; 88(5):E132-E138. PubMed ID: 26708085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of zotarolimus- and everolimus-eluting stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention.
    Ahmed K; Jeong MH; Chakraborty R; Ahmed S; Hong YJ; Sim DS; Park KH; Kim JH; Ahn Y; Kang JC; Cho MC; Kim CJ; Kim YJ;
    J Cardiol; 2014 Oct; 64(4):273-8. PubMed ID: 24631465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical outcomes of coronary artery stent implantation in patients with end-stage chronic kidney disease including hemodialysis for three everolimus eluting (EES) stent designs: Bioresorbable polymer-EES, platinum chromium-EES, and cobalt chrome-EES.
    Sato T; Hatada K; Kishi S; Fuse K; Fujita S; Ikeda Y; Takahashi M; Matsubara T; Okabe M; Aizawa Y
    J Interv Cardiol; 2018 Apr; 31(2):170-176. PubMed ID: 29166699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of chronic kidney disease on long-term clinical outcomes of everolimus-eluting stent implantation: A subanalysis of the Tokyo-MD PCI registry.
    Miyazaki T; Ashikaga T; Asano M; Sasaoka T; Kurihara K; Yoshikawa S; Isobe M;
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):E9-E16. PubMed ID: 30714680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comer PRODIGY trial.
    Crimi G; Leonardi S; Costa F; Adamo M; Ariotti S; Valgimigli M
    Int J Cardiol; 2016 Jun; 212():110-7. PubMed ID: 27038714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
    Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
    J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of preprocedural high-sensitive C-reactive protein levels on long-term clinical outcomes of patients with stable coronary artery disease and chronic kidney disease who were treated with drug-eluting stents.
    Ogita M; Miyauchi K; Kasai T; Doi S; Wada H; Naito R; Konishi H; Tsuboi S; Dohi T; Tamura H; Okazaki S; Daida H
    J Cardiol; 2015 Jul; 66(1):15-21. PubMed ID: 25572020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents: A Patient-Level Pooled Analysis of Randomized Controlled Trials.
    Baber U; Giustino G; Sartori S; Aquino M; Stefanini GG; Steg PG; Windecker S; Leon MB; Wijns W; Serruys PW; Valgimigli M; Stone GW; Dangas GD; Morice MC; Camenzind E; Weisz G; Smits PC; Kandzari D; Von Birgelen C; Mastoris I; Galatius S; Jeger RV; Kimura T; Mikhail GW; Itchhaporia D; Mehta L; Ortega R; Kim HS; Kastrati A; Chieffo A; Mehran R
    JACC Cardiovasc Interv; 2016 Jan; 9(1):28-38. PubMed ID: 26762908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
    Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
    JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients.
    Miyazaki T; Latib A; Panoulas VF; Miyazaki S; Costopoulos C; Sato K; Naganuma T; Kawamoto H; Daida H; Colombo A
    Catheter Cardiovasc Interv; 2015 Jul; 86(1):E11-8. PubMed ID: 25534499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased cystatin C levels as a risk factor of cardiovascular events in patients with preserved estimated glomerular filtration rate after elective percutaneous coronary intervention with drug-eluting stents.
    Sai E; Shimada K; Miyauchi K; Masaki Y; Kojima T; Miyazaki T; Kurata T; Ogita M; Tsuboi S; Yoshihara T; Miyazaki T; Ohsaka A; Daida H
    Heart Vessels; 2016 May; 31(5):694-701. PubMed ID: 25863806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
    Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
    Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes With Complete Versus Incomplete Revascularization in Patients With Multivessel Coronary Disease Undergoing Percutaneous Coronary Intervention With Everolimus Eluting Stents.
    Bangalore S; Guo Y; Samadashvili Z; Hannan EL
    Am J Cardiol; 2020 Feb; 125(3):362-369. PubMed ID: 31810515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES).
    Kitasato L; Shimohama T; Ikeda Y; Namba S; Hashikata T; Kameda R; Sato N; Takeuchi I; Yamaoka-Tojo M; Tojo T; Ako J
    Biomed Pharmacother; 2015 May; 72():6-10. PubMed ID: 26054668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of chronic kidney disease on a re-percutaneous coronary intervention for sirolimus-eluting stent restenosis.
    Aoyama Y; Hirayama H; Ishii H; Kobayashi K; Ishikawa K; Takigawa M; Nanasato M; Yoshida Y; Aoyama T; Yoshikawa D; Matsubara T; Murohara T
    Coron Artery Dis; 2012 Dec; 23(8):528-32. PubMed ID: 22975841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical evaluation of the XIENCE V everolimus eluting stent in the treatment of patients with coronary artery disease: Result from Thailand Registry - XIENCE V performance evaluation (THRIVE study).
    Kiatchoosakun S; Pienvichit P; Kuanprasert S; Suraphakdee N; Phromminikul A
    Indian Heart J; 2017; 69(2):165-169. PubMed ID: 28460763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Effectiveness of Percutaneous Intervention of the Left-Main Coronary Artery With Everolimus-Eluting Stents in Women -Vs- Men.
    Trabattoni D; Teruzzi G; Montorsi P; Fabbiocchi F; Gili S; Calligaris G; Grancini L; Galli S; Ravagnani P; Bartorelli A
    Am J Cardiol; 2019 Nov; 124(9):1357-1362. PubMed ID: 31493828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.